I think, as I say, we’re in a great position in the UK that we can offer next generation sequencing. I think there’s still some work to do to try and improve the pathways, make sure sufficient samples are taken and that we get the pathways in place that can get results back as quickly as possible for patients really to keep that timeframe as short as possible. And, from my perspective, and I think from all lung cancer specialist perspective, we want all those results back so we can make the right treatment decision for our patients...
I think, as I say, we’re in a great position in the UK that we can offer next generation sequencing. I think there’s still some work to do to try and improve the pathways, make sure sufficient samples are taken and that we get the pathways in place that can get results back as quickly as possible for patients really to keep that timeframe as short as possible. And, from my perspective, and I think from all lung cancer specialist perspective, we want all those results back so we can make the right treatment decision for our patients. And if you can’t have those full genomic profile results by the time you’re seeing your patients, it can impact because we want to make the best decision in terms of whether it should be chemotherapy, chemo immunotherapy, or a targeted treatment. And whether that be through a reimbursed treatment or a clinical trial. So really important as a community we work towards getting those turnaround times as short as possible and that’s a key priority for NHS England at the moment.
